JP2022553058A5 - - Google Patents
Info
- Publication number
- JP2022553058A5 JP2022553058A5 JP2022523597A JP2022523597A JP2022553058A5 JP 2022553058 A5 JP2022553058 A5 JP 2022553058A5 JP 2022523597 A JP2022523597 A JP 2022523597A JP 2022523597 A JP2022523597 A JP 2022523597A JP 2022553058 A5 JP2022553058 A5 JP 2022553058A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- composition according
- surfactant
- approximately
- antibody construct
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025167676A JP2026003626A (ja) | 2019-10-25 | 2025-10-03 | 低タンパク質濃度のタンパク質損失を最小限に抑えるための組成物及び方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962926089P | 2019-10-25 | 2019-10-25 | |
| US62/926,089 | 2019-10-25 | ||
| PCT/US2020/057065 WO2021081326A1 (en) | 2019-10-25 | 2020-10-23 | Compositions and methods for minimizing protein loss at low protein concentrations |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025167676A Division JP2026003626A (ja) | 2019-10-25 | 2025-10-03 | 低タンパク質濃度のタンパク質損失を最小限に抑えるための組成物及び方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022553058A JP2022553058A (ja) | 2022-12-21 |
| JP2022553058A5 true JP2022553058A5 (cg-RX-API-DMAC10.html) | 2023-10-02 |
Family
ID=75620878
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022523597A Withdrawn JP2022553058A (ja) | 2019-10-25 | 2020-10-23 | 低タンパク質濃度のタンパク質損失を最小限に抑えるための組成物及び方法 |
| JP2025167676A Pending JP2026003626A (ja) | 2019-10-25 | 2025-10-03 | 低タンパク質濃度のタンパク質損失を最小限に抑えるための組成物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025167676A Pending JP2026003626A (ja) | 2019-10-25 | 2025-10-03 | 低タンパク質濃度のタンパク質損失を最小限に抑えるための組成物及び方法 |
Country Status (12)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3559035A1 (en) | 2016-12-21 | 2019-10-30 | TeneoBio, Inc. | Anti-bcma heavy chain-only antibodies |
| JP7548475B1 (ja) * | 2023-03-16 | 2024-09-10 | 小野薬品工業株式会社 | 抗体製剤 |
| TW202517293A (zh) * | 2023-07-07 | 2025-05-01 | 美商再生元醫藥公司 | 含有抗bcmax抗cd3雙特異性抗體之穩定化配製物 |
| CN120271709B (zh) * | 2025-04-08 | 2026-03-31 | 康立泰生物医药(青岛)有限公司 | 一种抗cldn18.2纳米抗体及其制备方法和应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005097831A2 (en) * | 2004-04-07 | 2005-10-20 | Gastrotech Pharma A/S | Uses of isolated binding members capable of binding specifically to secretagogues |
| SMT201800335T1 (it) * | 2012-11-06 | 2018-09-13 | Bayer Pharma AG | Formulazione di attivatori bispecifici per linfociti t (bite) |
| AU2014229282B2 (en) * | 2013-03-15 | 2017-02-02 | Glaxosmithkline Intellectual Property (No.2) Limited | Low concentration antibody formulations |
| CN103387723A (zh) * | 2013-07-31 | 2013-11-13 | 朱煜 | 一种不含dehp的聚氯乙烯材料及输液器 |
| US11173208B2 (en) * | 2014-05-07 | 2021-11-16 | Takeda Gmbh | Liquid formulation comprising GM-CSF neutralizing compound |
| EA039859B1 (ru) * | 2015-07-31 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
| UA126657C2 (uk) * | 2016-02-03 | 2023-01-11 | Емджен Рісерч (Мюнік) Ґмбг | ОДНОЛАНЦЮГОВА КОНСТРУКЦІЯ АНТИТІЛА ДО BCMA І CD3<font face="Symbol">e</font> |
| CN116019768A (zh) * | 2016-06-07 | 2023-04-28 | 塔佳吉尼克斯公司 | 靶向癌细胞和癌干细胞的紫杉烷类药物的纳米乳剂组合物及其使用方法 |
| WO2018073648A1 (en) * | 2016-10-19 | 2018-04-26 | Novelogics Biotechnology, Inc. | Antibodies to mica and micb proteins |
| MA48763A (fr) * | 2017-05-05 | 2020-04-08 | Amgen Inc | Composition pharmaceutique comprenant des constructions d'anticorps bispécifiques pour un stockage et une administration améliorés |
| EP3688033A4 (en) * | 2017-09-29 | 2021-06-23 | Janssen Biotech, Inc. | NEW FORMULATIONS THAT STABILIZE LOW DOSE ANTIBODY COMPOSITIONS |
| EP3759154A1 (en) * | 2018-03-02 | 2021-01-06 | Sigilon Therapeutics, Inc. | Biocompatible hydrogel capsules and process for preparing same |
-
2020
- 2020-10-23 AU AU2020370372A patent/AU2020370372A1/en active Pending
- 2020-10-23 CA CA3155125A patent/CA3155125A1/en active Pending
- 2020-10-23 EP EP20879116.0A patent/EP4048310A4/en active Pending
- 2020-10-23 WO PCT/US2020/057065 patent/WO2021081326A1/en not_active Ceased
- 2020-10-23 US US17/771,313 patent/US20220378908A1/en active Pending
- 2020-10-23 MX MX2022004944A patent/MX2022004944A/es unknown
- 2020-10-23 CN CN202080074309.9A patent/CN114599394A/zh active Pending
- 2020-10-23 JP JP2022523597A patent/JP2022553058A/ja not_active Withdrawn
- 2020-10-23 KR KR1020227017280A patent/KR20220099585A/ko active Pending
- 2020-10-23 BR BR112022007776A patent/BR112022007776A2/pt not_active Application Discontinuation
-
2022
- 2022-04-13 IL IL292211A patent/IL292211A/en unknown
- 2022-04-25 CL CL2022001035A patent/CL2022001035A1/es unknown
-
2025
- 2025-10-03 JP JP2025167676A patent/JP2026003626A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250333493A1 (en) | Formulations of monoclonal antibodies | |
| US11286294B2 (en) | Anti-RSV monoclonal antibody formulation | |
| TWI721020B (zh) | 一種抗ｐｄ-１抗體製劑及其在醫藥上的應用 | |
| JP4536829B2 (ja) | モノクローナル抗体又はポリクローナル抗体の安定な凍結乾燥された医薬製剤 | |
| TWI606838B (zh) | 達托黴素（ｄａｐｔｏｍｙｃｉｎ）組合物及相關方法 | |
| CA2794929A1 (en) | Concentrated protein formulations and uses thereof | |
| JP2018188437A5 (cg-RX-API-DMAC10.html) | ||
| US12251474B2 (en) | Process for lyophilized pharmaceutical formulations of a therapeutic protein | |
| TWI810196B (zh) | 一種il-15蛋白質複合物醫藥組成物及其用途 | |
| JP3105494B2 (ja) | 蛋白質を安定化するための改良された方法 | |
| TWI615158B (zh) | 多肽之調配物 | |
| JP2022036932A5 (cg-RX-API-DMAC10.html) | ||
| KR20230164205A (ko) | 실온 안정성 동결건조된 단백질 | |
| JP2016533345A5 (cg-RX-API-DMAC10.html) | ||
| JP2016533345A (ja) | 持続型ヒト成長ホルモン製剤 | |
| KR20220099585A (ko) | 낮은 단백질 농도에서 단백질 손실을 최소화하기 위한 조성물 및 방법 | |
| US20210330801A1 (en) | Novel protein drug conjugate formulation | |
| RU2025126931A (ru) | СОСТАВЫ, ВКЛЮЧАЮЩИЕ ВАРИАНТЫ ПОЛИПЕПТИДА ActRIIa | |
| HK1238156A1 (en) | Stable anti-pd-1 antibody pharmaceutical preparation and application thereof in medicine | |
| CN103068366B (zh) | 长效人生长激素缀合物的液体制剂 | |
| JP2023509354A5 (cg-RX-API-DMAC10.html) | ||
| HK40033832B (en) | Process for lyophilized pharmaceutical formulation of a therapeutic protein | |
| HK40033832A (en) | Process for lyophilized pharmaceutical formulation of a therapeutic protein | |
| BR112020004902B1 (pt) | Processo para formulação farmacêutica liofilizada de uma proteína terapêutica | |
| RU2020113092A (ru) | Препараты антител против her2 для подкожного введения |